1.Research progress in pharmacotherapy of insomnia.
Jin HU ; Shan-Shan WEI ; Hai-Zhou JIANG ; Jing-Yi LUO ; Wei YANG ; Yun-Min ZHANG ; Xin-Bo WANG ; Chao-Nan WEN
China Journal of Chinese Materia Medica 2023;48(19):5122-5130
Insomnia is extremely common and is a risk factor for a variety of physical and psychological disorders in addition to contributing to the reduced quality of life of patients and the burden of healthcare costs. Although cognitive behavioral therapy is the first-line treatment for insomnia, its difficulty of access and high cost have hindered its application. Therefore, pharmacotherapy remains the common treatment choice for patients and clinicians. Existing chemical drugs including benzodiazepine receptor agonists, dual orexin receptor antagonists, melatonin and its receptor agonists, histamine antagonists, antidepressants, and antipsychotics are able to induce and/or maintain sleep and have good therapeutic effects on acute insomnia, but their efficacy on chronic insomnia is indefinite. Furthermore, they have several side effects and affect sleep structure and physiological function. Under the guiding principle of holistic view and treatment based on syndrome differentiation, traditional Chinese medicine(TCM) has shown a good effect in clinical practice, but with little high-grade clinical evidence. The mechanism, dose, half-life period, adjustment of sleep structure, and side effects of hypnotic drugs are key factors to be considered for clinical use. This paper analyzed and summarized the drugs for insomnia from the above aspects, and is expected to provide references for the application and development of sedative and hypnotic drugs.
Humans
;
Sleep Initiation and Maintenance Disorders/chemically induced*
;
Quality of Life
;
Sleep
;
Hypnotics and Sedatives/pharmacology*
;
Antidepressive Agents/pharmacology*
2.Zolpidem Use and Risk of Fracture in Elderly Insomnia Patients.
Dong Yoon KANG ; Soyoung PARK ; Chul Woo RHEE ; Ye Jee KIM ; Nam Kyong CHOI ; Joongyub LEE ; Byung Joo PARK
Journal of Preventive Medicine and Public Health 2012;45(4):219-226
OBJECTIVES: To evaluate the risk of fractures related with zolpidem in elderly insomnia patients. METHODS: Health claims data on the entire South Korean elderly population from January 2005 to June 2006 were extracted from the Health Insurance Review and Assessment Service database. We applied a case-crossover design. Cases were defined as insomnia patients who had a fracture diagnosis. We set the hazard period of 1 day length prior to the fracture date and four control periods of the same length at 5, 10, 15, and 20 weeks prior to the fracture date. Time independent confounding factors such as age, gender, lifestyle, cognitive function level, mobility, socioeconomic status, residential environment, and comorbidity could be controlled using the casecrossover design. Time dependent confounding factors, especially co-medication of patients during the study period, were adjusted by conditional logistic regression analysis. The odds ratios and their 95% confidence intervals (CIs) were estimated for the risk of fracture related to zolpidem. RESULTS: One thousand five hundred and eight cases of fracture were detected in insomnia patients during the study period. In our data, the use of zolpidem increased the risk of fracture significantly (adjusted odds ratio [aOR], 1.72; 95% CI, 1.37 to 2.16). However, the association between benzodiazepine hypnotics and the risk of fracture was not statistically significant (aOR, 1.00; 95% CI, 0.83 to 1.21). Likewise, the results were not statistically significant in stratified analysis with each benzodiazepine generic subgroup. CONCLUSIONS: Zolpidem could increase the risk of fracture in elderly insomnia patients. Therefore zolpidem should be prescribed carefully and the elderly should be provided with sufficient patient education.
Aged
;
Aged, 80 and over
;
Benzodiazepines/adverse effects/therapeutic use
;
Cross-Over Studies
;
Female
;
Fractures, Bone/chemically induced/*epidemiology
;
Humans
;
Hypnotics and Sedatives/adverse effects/therapeutic use
;
Male
;
Odds Ratio
;
Pyridines/*adverse effects/*therapeutic use
;
Republic of Korea/epidemiology
;
Risk Assessment
;
Risk Factors
;
Sleep Initiation and Maintenance Disorders/*drug therapy